Literature DB >> 24200358

Structure-activity relationships and mechanism of action of macrolides derived from erythromycin as antibacterial agents.

Jian-Hua Liang, Xu Han1.   

Abstract

Enormous efforts were focused on the 3-descladinosyl erythromycin derivatives which led to 3-keto (ketolides), 3-O-acyl (acylides), 3-O-carbamate (carbamolides), and 3-O-alkyl (alkylides) and cladinosyl-containing erythromycin derivatives such as 4"-O-acyl, 4"-O-carbamate, and 4"-O-alkyl derivatives as recently exemplified by macrolones (macrolide-quinolone hybrids). Ketolides acquire activity against MLSB-resistant pathogens via a featured arylalkyl extension suspended on the macrolide core, which interacts with a base pair formed by A752Ec and U2609Ec located in the nascent peptide release tunnel of the bacterial rRNA. A base pair formed by C2610Ec and G2505Ec probably is another novel binding site for 3-descladinosyl non-ketolides. It is believed that 4"-derived compounds perhaps interfere with the formation of polypeptide because the extension oriented into peptidyl transferase center (PTC) region. Although macrolones are hybrids of macrolides and quinolones, they do not have dual modes of action, and serve only as protein synthesis inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24200358     DOI: 10.2174/15680266113136660223

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  9 in total

Review 1.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

2.  Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics.

Authors:  Dražen Pavlović; Stjepan Mutak; Daniele Andreotti; Stefano Biondi; Francesca Cardullo; Alfredo Paio; Elisa Piga; Daniele Donati; Sergio Lociuro
Journal:  ACS Med Chem Lett       Date:  2014-08-15       Impact factor: 4.345

3.  In vitro antibacterial activity of α-methoxyimino acylide derivatives against macrolide-resistant pathogens and mutation analysis in 23S rRNA.

Authors:  Hiroyuki Sugiyama; Ippei Yoshida; Mayumi Ueki; Katsuhiko Tanabe; Akira Manaka; Keiichi Hiramatsu
Journal:  J Antibiot (Tokyo)       Date:  2017-01-11       Impact factor: 2.649

4.  Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics.

Authors:  Philip C Hogan; Chi-Li Chen; Kristen M Mulvihill; Jonathan F Lawrence; Eric Moorhead; Jens Rickmeier; Andrew G Myers
Journal:  J Antibiot (Tokyo)       Date:  2017-10-11       Impact factor: 2.649

Review 5.  The Risk of Some Veterinary Antimicrobial Agents on Public Health Associated with Antimicrobial Resistance and their Molecular Basis.

Authors:  Haihong Hao; Pascal Sander; Zahid Iqbal; Yulian Wang; Guyue Cheng; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-10-18       Impact factor: 5.640

6.  Application of Erythromycin and/or Raoultella sp. Strain MC3 Alters the Metabolic Activity of Soil Microbial Communities as Revealed by the Community Level Physiological Profiling Approach.

Authors:  Mariusz Cycoń; Anna Markowicz; Tomasz J Wąsik; Zofia Piotrowska-Seget
Journal:  Microorganisms       Date:  2020-11-25

7.  Combined impact of TiO2 nanoparticles and antibiotics on the activity and bacterial community of partial nitrification system.

Authors:  Han Xu; Binghua Liu; Wenyu Qi; Meng Xu; Xiaoyu Cui; Jun Liu; Qiang Li
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

8.  Development of Novel Erythromycin Derivatives with Inhibitory Activity against Proliferation of Tumor Cells.

Authors:  Lan Wu; Kai Bao; Rui Song; Defa Wang; Lei Zhang; Weiyun Wang; Weige Zhang; Wen Bin
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

9.  Chloramine-T/N-Bromosuccinimide/FeCl3/KIO3 Decorated Graphene Oxide Nanosheets and Their Antibacterial Activity.

Authors:  Ayesha Hashmi; Ajaya Kumar Singh; Bhawana Jain; Sónia Alexandra Correia Carabineiro
Journal:  Nanomaterials (Basel)       Date:  2020-01-04       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.